Vasculitis & polymyalgia rheumatica
Monitoring disease activity in eosinophilic granulomatosis with polyangiitis: a scoping review
Authors' conclusion
No robust tool currently exists for EGPA monitoring, even though interesting biomarkers and imaging techniques warrant further validation.
Study context
- Population
- Studies (January 2005–March 2025) including at least five eosinophilic granulomatosis with polyangiitis (EGPA) patients (≥10% of the cohort), focusing on disease activity or treatment response
- Participants
- 58 studies
- Outcome
- Methods to monitor disease activity or treatment response in EGPA
Main finding
As reported in the abstract
- Clinical studies frequently adopted MIRRA trial remission definitions (Birmingham Vasculitis Activity Score (BVAS)=0, prednisone ≤4 mg/day), but criteria varied across studies
- Most adopted secondary endpoints: oral GC sparing, changes in eosinophil count and in pulmonary function
- Biomarkers (conventional lab parameters and emerging molecular candidates): none achieved consistent reliability in distinguishing active from inactive disease
- Imaging and procedures (pulmonary function tests, high-resolution CT, FeNO, echocardiography, cardiac MRI) showed promise but lacked validation
Original publication
Monitoring disease activity in eosinophilic granulomatosis with polyangiitis: a scoping review. Clin Exp Rheumatol. Published 26 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →